OPKO subsidiary BRH cuts revolver from $75M to $50M, extends maturity to Aug 2025/conditional

OPKO HEALTH, INC.

Aggregate revolving commitment reduced from $75M to $50M.
Maturity extended from August 2024 to earlier of August 2025 or 90 days before maturity of any material OPKO-level debt.
Interest rate benchmark switched from LIBOR to forward-looking term SOFR.
Revised commitment fee rate; full terms to be filed in Q2 2023 10-Q.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

OPKO HEALTH, INC. amended Waiver and Amendment No. 2 with JPMorgan Chase Bank, N.A., as administrative agent for the lenders (effective 2023-06-29).

Action: amendment
Agreement: credit facility
Counterparty: JPMorgan Chase Bank, N.A., as administrative agent for the lenders
Effective: 2023-06-29

Exact text from the filing

On June 29, 2023, BioReference Health, LLC, a Delaware limited liability company (“ BRH ”), a subsidiary of OPKO Health, Inc. (the “ Company ”), together with the other parties thereto, entered into a Waiver and Amendment No. 2 (the “ Amendment ”) to the Amended and Restated Credit Agreement (the “ Amended Credit Agreement ”), dated as of August 30, 2021, by and among BRH, certain of its subsidiaries, as borrowers or guarantors, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent for the lenders.

View on SEC.gov

Browse all material agreements →

OPKO HEALTH, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-019033

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.